Alcon’s recovery is slowly on track

Novartis reported sales for its Alcon eye care business of $1.4 billion in the first quarter, down by 1 percent versus last year's first quarter. In constant currencies, Alcon sales increased by 1 percent. Novartis said Alcon's growth plan is on track, with ongoing actions to accelerate sales and innovation, ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.

barrier_image_OIC

Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to ewintelligence.com - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

To continue reading this article register now.